7ACC2 is a new potent MCT inhibitor with IC50 of 11 nM for inhibition of [14C]-lactate influx; new antitumor treatment targeting lactate transport in cancer cells.

6-Thioguanine(6-TG) belongs to the thiopurine family of drugs that also include mercaptopurine and azathioprine, which are examples of antimetabolites; it is a purine analogue of the nucleobase guanine.

6H05 is a selective, and allosteric inhibitor of oncogenic K-Ras(G12C).

666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM.

5-Iodotubercidin (Itu) has been shown to inhibit mitogen-activated protein kinase (ERK2) (Ki = 525 nM), adenosine kinase (ADK) (Ki = 30 nM), casein kinases 1 & 2 (CSNK1A1 & CSNK2A1), protein kinase A (PKA) and insulin receptor kinase (IC50 ranging from 0.

5-HT2C receptor antagonist that displays 158- and 100-fold selectivity over 5-HT2A and 5-HT2Breceptors respectively. Also displays selectivity over a range of other 5-HT, dopamine and adrenergic receptors. Brain penetrant; exerts anxiolytic-like activity.

5-Formyl-2-pyrimidinecarbonitrile is a chemical intermidate..

4μ8C is a potent and selective IRE1 Rnase inhibitor with IC50 of 76 nM.

4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 μM.

3-TYP is a selective SIRT3 inhibitor.

3PO is a PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor; reduces glycolytic flux and suppresses glucose uptake.

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM.

3-Cyano-7-ethoxycoumarin is a fluorescent P450 substrate (excitation/emission wavelengths = 408/455 nm); metabolized to cyano-hydroxycoumarin.

2-PMPA is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 300 pM.

2-NBDG is a fluorescent indicator for direct glucose uptake measurement and also is an indicator of cell viability.

2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 ± 0.11 μM for the inhibition of BPAEC migration.

1-Naphthyl PP1(1-NA-PP 1) is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively).

1-methyl-7-nitroisatoic anhydride is a reagent that detects local nucleotide flexibility, for probing 2'-hydroxyl reactivity.

1-EBIO is an Epithelial KCa channel activator. Promotes ESC differentiation into cardiomyocytes.

10074-G5 is a c-Myc Max interaction inhibitor.

1-(Ethoxycarbonylmethyl)-6-methoxyquinolinium (MQAE) is a fluorescent indicator dye that can be used to measure intracellular and extracellular chloride concentrations (absorption/emission max: 350/460 nm).

(S)-Timolol maleate, is a potent non-selective β-adrenergic receptor antagonist (Ki values are 1.97 and 2.0 nM for β1 and β2 receptor subtypes respectively).

(-)-Blebbistatin is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly.

PF-249(PF06885249) is a potent, selective AMPK β1-containing complexes activator; increases the phosphorylation of the AMPK substrate ACC at S79 with EC50 of 296 nM, potently inhibits de novo lipogenesis (IC50=15 nM) in primary rat hepatocytes.

Capadenoson is a selective agonist of adenosine-A1 receptor.

CSRM617 (CSRM-617) is a small-molecule inhibitor of the transcription factor ONECUT2 (OC2) with Kd of 7.43 uM in SPR assays, binds to OC2-HOX domain directly.

UT-143 is a selective androgen receptor irreversible covalent antagonist and inhibits AR transactivation with IC50 of 150 nM. UT-143 covalently and selectively binds to C406 and C327 in the AF-1 region and inhibits PCa cell proliferation and tumor growth.

CYN 154806 is a potent and selective somatostatin sst2 receptor antagonist. pIC50 values are 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.

BTdCPU is an activator of HRI. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells. Thus, specific activation of the eIF2α kinase HRI is a novel therapeutic target in MM that can augment current treatment strategies.

BLU-945(BLU945,BLU 945) is a highly potent and selective EGFR+/T790M/C797S (IC50 of 0.5 nM) and EGFR+/T790M (IC50 of 0.4 nM) inhibitor with >900-fold selectivity over EGFR WT (IC50 of 736.3 nM).